0001477932-26-003242
SEC filingQ1 marked by 98.9% revenue decline to $22.8K from $2.1M due to lower Chemrex business volume, yielding gross losses from fixed manufacturing costs at low production levels, though operating losses narrowed 12.6% to -$540.5K via cost discipline during strategic model transition.
Revenues decreased 98.9% to $22.8K for the quarter ended March 31, 2026 from $2.1M in the prior year quarter, primarily due to lower business volume at the Chemrex subsidiary as noted in management's discussion. This sharp topline contraction reflects challenges from prior management disruptions and reduced production, setting the stage for the company's planned shift in Chemrex's operating model toward higher-margin biotech manufacturing contracts.
Gross profit swung to a loss of $790 from prior year profit of $343.5K, resulting in a -3.5% gross margin. Management attributes this inversion to direct manufacturing costs persisting despite minimal production volumes at Chemrex, highlighting the leverage impact of fixed costs on low activity levels. This dynamic underscores the transitional pain as Chemrex repositions from legacy operations.
Cash flow from operations used -$147.7K, a marked improvement from -$824.1K prior year, primarily due to substantial increases in other payables and higher provisions for expected credit losses on Chemrex trade receivables based on customer payment behavior assessments. Free cash flow was -$148.0K after minimal $325 capex, down from $9.1K prior, reflecting restrained capital outlays during this period of operational reset and strategic investments. Working capital decreased due to operational losses alongside expansion efforts in line with overall plans.
Management emphasizes a clean balance sheet with minimal debt and simplified capital structure, providing a foundation for operational continuity, strategic investments, and potential M&A. The Ethereum-focused treasury strategy continues as a capital management element, while enhanced internal controls address prior Chemrex issues flagged by auditors. Looking forward, execution of Chemrex's model change and Fidelion term sheet developments (per Note 17) position the company to reallocate toward higher-margin biotech revenue, though near-term volatility persists until volume recovery materializes.